Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Maxim Group Upgrades Adial Pharmaceuticals to Buy, Announces $1.5 Price Target

Author: Benzinga Newsdesk | September 30, 2025 08:32am
Maxim Group analyst Jason McCarthy upgrades Adial Pharmaceuticals (NASDAQ:ADIL) from Hold to Buy and announces $1.5 price target.

Posted In: ADIL

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist